Evidence map›Paper›PMID 31564024›Full record

ArticleThe protein journal2019

Expression and Characterization of Human Vascular Endothelial Growth Factor Produced in SiHa Cells Transduced with Adenoviral Vector.

N C Parra, R Mansilla, G Aedo, N S Vispo, E E González-Horta, I González-Chavarría, C Castillo, F Camacho, O Sánchez

Abstract read
PubMed Publisher
In one paragraph

Article in The protein journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

N C ParraRecombinant Biopharmaceuticals Laboratory, Department of Pharmacology, School of Biological Sciences, Universidad de Concepción, P.O. Box 160C, Concepción, Chile.
R MansillaRecombinant Biopharmaceuticals Laboratory, Department of Pharmacology, School of Biological Sciences, Universidad de Concepción, P.O. Box 160C, Concepción, Chile.
G AedoRecombinant Biopharmaceuticals Laboratory, Department of Pharmacology, School of Biological Sciences, Universidad de Concepción, P.O. Box 160C, Concepción, Chile.
N S VispoSchool of Life Sciences & Biotechnology, Yachay Tech University, San Miguel de Urcuquí, Hacienda San José s/n y Proyecto Yachay, Urcuquí, Ecuador.
E E González-HortaBiotechnology and Biopharmaceuticals Laboratory, Department of Pathophysiology, School of Biological Sciences, Universidad de Concepción, Concepción, Chile.
I González-ChavarríaBiotechnology and Biopharmaceuticals Laboratory, Department of Pathophysiology, School of Biological Sciences, Universidad de Concepción, Concepción, Chile.
C CastilloBiotechnology and Biopharmaceuticals Laboratory, Department of Pathophysiology, School of Biological Sciences, Universidad de Concepción, Concepción, Chile.
F CamachoRecombinant Biopharmaceuticals Laboratory, Department of Pharmacology, School of Biological Sciences, Universidad de Concepción, P.O. Box 160C, Concepción, Chile.
O SánchezRecombinant Biopharmaceuticals Laboratory, Department of Pharmacology, School of Biological Sciences, Universidad de Concepción, P.O. Box 160C, Concepción, Chile. osanchez@udec.cl.ORCID 0000-0002-9744-8674
University of Concepción · CLUniversidad Yachay Tech · EC

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The vascular endothelial growth factor (VEGF) is an essential factor to pathologic angiogenesis. Disruption of VEGF/VEGF receptor interaction in cancer patients inhibits the development of new and pre-existing tumor blood vessels. Consequently, VEGF becomes an important therapeutic target for handling solid tumors. In this work, human VEGF was produced in the culture supernatant of SiHa cells transduced with a replication-defective adenoviral vector (pAdhVEGF

Indexed as

AnimalsCell Line, TumorCell ProliferationHumansMiceVascular Endothelial Growth Factor AVascular Endothelial Growth Factor AVEGFA protein, humanAdenoviral vectorECV-304 cellsHUVECVascular permeabilityVEGF121

Identifiers

PMID31564024
OpenAlexW2975048529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.